雲頂新耀(01952.HK)任命首席醫學官及首席產品官
雲頂新耀(01952.HK)宣布,任命曾慶雯為首席醫學官及梁旭為首席產品官,以進一步加強管理團隊,提升研發、臨床開發、醫學事務和市場營銷部門之間的戰略整合。
曾慶雯將負責管理公司的臨床開發團隊,並通過跨部門合作開發自主研發及引進更多創新產品,同時領導新產品在中國的臨床開發。而梁旭則會負責雲頂新耀市場和醫學事務部的戰略和團隊管理工作,與商業化團隊密切合作,引領品牌戰略和上市計劃,確保營銷策略的實施和執行。(gc/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.